title: Antiplatelet or anticoagulant therapy might not increase the risk of haemoptysis in patients with bronchiectasis.
abstract: The aim of this study was to assess whether the use of antiplatelets and anticoagulants increased haemoptysis in patients with bronchiectasis. Cases (n = 242) with a history of haemoptysis were compared with controls (n = 242) without a history of haemoptysis. Of the 242 case patients, 16.5% took antiplatelets compared with 19.8% of controls (P = 0.346). The proportion of warfarin users did not differ between cases and controls (3.3% vs. 2.5%, P = 0.588). The use of these agents might not be associated with increased risk of haemoptysis in patients with bronchiectasis.
authors: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors: J
authors: J
authors: Lee
authors: Y S
authors: YS
authors: Park
authors: C-H
authors: CH
authors: Lee
authors: S-M
authors: SM
authors: Lee
authors: C-G
authors: CG
authors: Yoo
authors: Y W
authors: YW
authors: Kim
authors: S K
authors: SK
authors: Han
authors: J-J
authors: JJ
authors: Yim
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001987:Bronchiectasis / Q000150:complications* / Q000503:physiopathology; D016022:Case-Control Studies; D005260:Female; D006469:Hemoptysis / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin